Jazz Pharmaceuticals plc (NASDAQ: JAZZ) started the day on Wednesday, with a price increase of 1.84% at $142.07, before settling in for the price of $139.51 at the close. Taking a more long-term approach, JAZZ posted a 52-week range of $99.06-$148.06.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
The Healthcare sector firm’s twelve-monthly sales growth has been 13.88% for the last half of the decade. Meanwhile, its Annual Earning per share during the time was -1.00%. Nevertheless, stock’s Earnings Per Share (EPS) this year is 11.99%. This publicly-traded company’s shares outstanding now amounts to $60.63 million, simultaneously with a float of $57.97 million. The organization now has a market capitalization sitting at $8.63 billion. At the time of writing, stock’s 50-day Moving Average stood at $130.44, while the 200-day Moving Average is $117.50.
Jazz Pharmaceuticals plc (JAZZ) Ownership Facts and Figures
Now let’s turn our focus to how large-scale investors are working with this stock of the Biotechnology Industry. Jazz Pharmaceuticals plc’s current insider ownership accounts for 4.54%, in contrast to 97.55% institutional ownership. According to the most recent insider trade that took place on Mar 10 ’25, this organization’s EVP, Global Head of R&D & CMO sold 2,403 shares at the rate of 138.41, making the entire transaction reach 332,605 in total value, affecting insider ownership by 79,621. Preceding that transaction, on Mar 10 ’25, Company’s SVP, Chief Accounting Officer sold 1,140 for 137.81, making the whole transaction’s value amount to 157,103. This particular insider is now the holder of 7,012 in total.
Jazz Pharmaceuticals plc (JAZZ) Earnings and Revenue Records
Jazz Pharmaceuticals plc’s EPS increase for this current 12-month fiscal period is 11.99% and is forecasted to reach 23.09 in the upcoming year. Considering the longer run, market analysts have predicted that Company’s EPS will increase by 5.44% through the next 5 years, which can be compared against the -1.00% growth it accomplished over the previous five years trading on the market.
Jazz Pharmaceuticals plc (NASDAQ: JAZZ) Trading Performance Indicators
Let’s observe the current performance indicators for Jazz Pharmaceuticals plc (JAZZ). It’s Quick Ratio in the last reported quarter now stands at 3.99. The Stock has managed to achieve an average true range (ATR) of 3.93. Alongside those numbers, its PE Ratio stands at $16.24, and its Beta score is 0.37. Another valuable indicator worth pondering is a publicly-traded company’s price to sales ratio for trailing twelve months, which is currently 2.12. Similarly, its price to free cash flow for trailing twelve months is now 6.35.
In the same vein, JAZZ’s Diluted EPS (Earnings per Share) trailing twelve months is recorded 8.75, a figure that is expected to reach 4.82 in the next quarter, and analysts are predicting that it will be 23.09 at the market close of one year from today.
Technical Analysis of Jazz Pharmaceuticals plc (JAZZ)
If we take a close look at the recent performances of Jazz Pharmaceuticals plc (NASDAQ: JAZZ), its last 5-days Average volume was 1.0 million that shows progress from its year to date volume of 0.8 million. During the previous 9 days, stock’s Stochastic %D was recorded 80.14% While, its Average True Range was 3.85.
Raw Stochastic average of Jazz Pharmaceuticals plc (JAZZ) in the period of the previous 100 days is set at 85.26%, which indicates a major rise in contrast to 70.82% during the last 2-weeks. If we go through the volatility metrics of the stock, In the past 14-days, Company’s historic volatility was 24.27% that was lower than 27.95% volatility it exhibited in the past 100-days period.
